Sign in

NCT06987643CompletedPhase 2

A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke

Source: ClinicalTrials.gov · Last updated 28 Oct 2026

Brief summary (registry, in English)

The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
45 (actual)
First submitted
5 May 2025
Start date
20 Jun 2025
Primary completion date
23 Sept 2026
Lead sponsor
EIP Pharma Inc
Diseases
Stroke
NCT number
NCT06987643

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 45
  • From 20 Jun 2025 to the primary completion date, 23 Sept 2026
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participants needing carotid surgery within 3 months
  • Ongoing major and active psychiatric disorder and/or other concurrent medical condition that, in the opinion of the Investigator, might compromise safety and/or compliance with study requirements.
  • History of alcohol or drug abuse within the previous 2 years.

Other illness

  • Evidence of progressive or unstable stroke or intra-cerebral haemorrhage in the opinion of the investigator
  • Poorly controlled clinically significant medical illness, such as hypertension (blood pressure \>180 mmHg systolic or 100 mmHg diastolic); myocardial infarction within 6 months; uncompensated congestive heart failure or other significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would interfere with assessment of drug safety in the opinion of the Investigator.

Lab values

  • Abnormal laboratory tests that, in the Investigator's assessment, mean that a participant is not appropriate for participation in this study, including, but not limited to:
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.0
    • × the upper limit of normal (ULN),
    • Total bilirubin \>1.5 × ULN, and/or
    • International Normalised Ratio (INR) \>1.5 NOTE: Participants with Gilbert's syndrome can be included with total bilirubin \>1.5 x ULN as long as direct bilirubin is ≤ 1.5 x ULN)

Who the study is looking for

  • Male or female participants must be aged 45 years or over at the time of signing the informed consent.
  • Confirmed acute ischaemic stroke in the anterior circulation (middle or anterior cerebral artery) with onset of symptoms between 2 and 7 days prior to screening and evaluation.
  • National Institutes of Health Stroke Scale (NIHSS) score between 5 and 20 (inclusive) and exhibiting unilateral motor deficit (i.e. motor NIHSS ≥ 2 on affected side of the body).
  • Fugl-Meyer Assessment of Motor Recovery after Ischaemic Stroke (FMMS) total motor components score of 80 or below.
  • No history of learning difficulties that may interfere with their ability to complete the cognitive tests.

Age in the registry: 45 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Sunshine Coast University Hospital
Coordinator of this site? Confirm its status
BirtinyaAustraliaUnknown status
Box Hill Hospital
Coordinator of this site? Confirm its status
Box HillAustraliaUnknown status
Royal Brisbane and Women's Hospital
Coordinator of this site? Confirm its status
BrisbaneAustraliaUnknown status
Campbelltown Hospital
Coordinator of this site? Confirm its status
CampbelltownAustraliaUnknown status
Austin Hospital
Coordinator of this site? Confirm its status
HeidelbergAustraliaUnknown status
Liverpool Hospital
Coordinator of this site? Confirm its status
LiverpoolAustraliaUnknown status
Royal Melbourne Hospital
Coordinator of this site? Confirm its status
MelbourneAustraliaUnknown status
Alfred Hospital
Coordinator of this site? Confirm its status
MelbourneAustraliaUnknown status
Gold Coast University Hospital
Coordinator of this site? Confirm its status
SouthportAustraliaUnknown status
Western Health Sunshine Hospital
Coordinator of this site? Confirm its status
St AlbansAustraliaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.